Eloxx Pharmaceuticals, Inc. (ELOX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Eloxx Pharmaceuticals, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $5.27M in total assets against $17.18M in total liabilities.
Key ratios (FY2025)
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.36M | $0 | — | — | — | — | — | — | — |
| Operating Income | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M | -$33.45M | -$50.55M | -$47.56M | -$20.39M | -$9.84M |
| Net Income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M | -$34.58M | -$50.87M | -$47.19M | -$21.21M | -$9.85M |
| EPS (Diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | — | — | — | — | — |
| Total Assets | $5.27M | $2.98M | $1.71M | $21.12M | $45.14M | $26.48M | $58.95M | $50.72M | $24.78M | $3.13M |
| Total Liabilities | $17.18M | $27.31M | $24.31M | $31.78M | $22.75M | $16.25M | $22.73M | $7.81M | $4.97M | $4.67M |
| Shareholders' Equity | -$11.91M | -$24.34M | -$22.60M | -$10.66M | $22.38M | $10.23M | $36.21M | $42.91M | $21.36M | $610.0K |
| Cash & Equivalents | $4.79M | $111.0K | $1.13M | $19.21M | $42.27M | $24.67M | $22.49M | $48.61M | $24.05M | $2.21M |
| Operating Cash Flow | -$6.33M | -$4.71M | -$14.34M | -$31.84M | -$35.00M | -$28.17M | -$39.39M | -$31.37M | -$15.94M | -$8.84M |
| Capital Expenditures | — | — | — | $66.0K | $89.0K | — | $40.0K | $235.0K | $237.0K | $36.0K |
| Shares Outstanding | 4.79M | 3.53M | 3.14M | 2.17M | 2.17M | 40.16M | 40.03M | 35.86M | 27.53M | 4.21M |